On Nov.16, the FDA’s Cardiovascular and Renal Drug Advisory Committee will meet to assess the data supporting Ardelyx’s New Drug Application for tenapanor in chronic kidney disease.
https://www.pharmalive.com/wp-content/uploads/2022/02/FDA-Action-Alert-Immunocore-Reata-CTI-Gilead-and-LegendJanssen-BioSpace-2-21-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-01 08:00:352022-11-01 12:03:27ASN to spotlight debate around Ardelyx's embattled CKD drug
